1. Home
  2. SILO vs PPBT Comparison

SILO vs PPBT Comparison

Compare SILO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SILO
  • PPBT
  • Stock Information
  • Founded
  • SILO 2010
  • PPBT 2010
  • Country
  • SILO United States
  • PPBT Israel
  • Employees
  • SILO N/A
  • PPBT N/A
  • Industry
  • SILO Apparel
  • PPBT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SILO Consumer Discretionary
  • PPBT Health Care
  • Exchange
  • SILO Nasdaq
  • PPBT Nasdaq
  • Market Cap
  • SILO 8.0M
  • PPBT 7.4M
  • IPO Year
  • SILO N/A
  • PPBT N/A
  • Fundamental
  • Price
  • SILO $0.43
  • PPBT $0.82
  • Analyst Decision
  • SILO
  • PPBT Strong Buy
  • Analyst Count
  • SILO 0
  • PPBT 1
  • Target Price
  • SILO N/A
  • PPBT $33.00
  • AVG Volume (30 Days)
  • SILO 275.0K
  • PPBT 22.1M
  • Earning Date
  • SILO 11-13-2025
  • PPBT 11-14-2025
  • Dividend Yield
  • SILO N/A
  • PPBT N/A
  • EPS Growth
  • SILO N/A
  • PPBT N/A
  • EPS
  • SILO N/A
  • PPBT N/A
  • Revenue
  • SILO $72,102.00
  • PPBT N/A
  • Revenue This Year
  • SILO $1.86
  • PPBT N/A
  • Revenue Next Year
  • SILO N/A
  • PPBT N/A
  • P/E Ratio
  • SILO N/A
  • PPBT N/A
  • Revenue Growth
  • SILO N/A
  • PPBT N/A
  • 52 Week Low
  • SILO $0.36
  • PPBT $0.53
  • 52 Week High
  • SILO $3.37
  • PPBT $13.95
  • Technical
  • Relative Strength Index (RSI)
  • SILO 38.57
  • PPBT 55.31
  • Support Level
  • SILO $0.39
  • PPBT $0.72
  • Resistance Level
  • SILO $0.43
  • PPBT $0.87
  • Average True Range (ATR)
  • SILO 0.04
  • PPBT 0.08
  • MACD
  • SILO -0.00
  • PPBT 0.01
  • Stochastic Oscillator
  • SILO 39.29
  • PPBT 67.68

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: